Assignee
IBC PHARMACEUTICALS INC
US·49 granted patents·15 pending applications·2,076 citations·filing 2002–2019
Top patents by PatentIndex Score
64 records- 0199US8349332B2Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseasesIBC PHARMACEUTICALS INC·Filed 2011·Granted Jan 8, 2013·58 cites·12 claims
- 0299US8034352B2Tetrameric cytokines with improved biological activityIBC PHARMACEUTICALS INC·Filed 2010·Granted Oct 11, 2011·61 cites·6 claims
- 0399US7906121B2Methods and compositions for generating bioactive assemblies of increased complexity and usesIBC PHARMACEUTICALS INC·Filed 2009·Granted Mar 15, 2011·125 cites·25 claims
- 0499US7906118B2Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technologyIBC PHARMACEUTICALS INC·Filed 2009·Granted Mar 15, 2011·90 cites·17 claims
- 0599US7901680B2Dock-and-lock (DNL) vaccines for cancer therapyIBC PHARMACEUTICALS INC·Filed 2009·Granted Mar 8, 2011·92 cites·19 claims
- 0699US7666400B2PEGylation by the dock and lock (DNL) techniqueIBC PHARMACEUTICALS INC·Filed 2007·Granted Feb 23, 2010·158 cites·21 claims
- 0799US7550143B2Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and usesIBC PHARMACEUTICALS INC·Filed 2006·Granted Jun 23, 2009·177 cites·21 claims
- 0899US7534866B2Methods and compositions for generating bioactive assemblies of increased complexity and usesIBC PHARMACEUTICALS INC·Filed 2006·Granted May 19, 2009·287 cites·18 claims
- 0999US7527787B2Multivalent immunoglobulin-based bioactive assembliesIBC PHARMACEUTICALS INC·Filed 2006·Granted May 5, 2009·293 cites·23 claims
- 1099US7521056B2Stably tethered structures of defined compositions with multiple functions or binding specificitiesIBC PHARMACEUTICALS INC·Filed 2006·Granted Apr 21, 2009·297 cites·28 claims
- 1198US9382329B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2015·Granted Jul 5, 2016·23 cites·15 claims
- 1298US9315567B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2013·Granted Apr 19, 2016·47 cites·10 claims
- 1398US8003111B2Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivoIBC PHARMACEUTICALS INC·Filed 2010·Granted Aug 23, 2011·71 cites·10 claims
- 1498US7981398B2PEGylation by the dock and lock (DNL) techniqueIBC PHARMACEUTICALS INC·Filed 2009·Granted Jul 19, 2011·58 cites·25 claims
- 1598US7871622B2Stably tethered structures of defined compositions with multiple functions or binding specificitiesIBC PHARMACEUTICALS INC·Filed 2009·Granted Jan 18, 2011·74 cites·14 claims
- 1698US7858070B2Multivalent immunoglobulin-based bioactive assembliesIBC PHARMACEUTICALS INC·Filed 2009·Granted Dec 28, 2010·71 cites·12 claims
- 1796US9670286B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2016·Granted Jun 6, 2017·9 cites·14 claims
- 1895US10111954B2Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2016·Granted Oct 30, 2018·8 cites·13 claims
- 1995US9682143B2Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2013·Granted Jun 20, 2017·18 cites·13 claims
- 2093US10662252B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2017·Granted May 26, 2020·5 cites·7 claims
- 2192US10131712B2Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitorsIBC PHARMACEUTICALS INC·Filed 2017·Granted Nov 20, 2018·5 cites·22 claims
- 2292US8871216B2Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseasesIBC PHARMACEUTICALS INC·Filed 2012·Granted Oct 28, 2014·9 cites·17 claims
- 2391US10245321B2Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·3 cites·8 claims
- 2491US9931413B2Tetrameric cytokines with improved biological activityIBC PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·6 cites·6 claims
- 2591US9879088B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2017·Granted Jan 30, 2018·4 cites·8 claims
- 2691US9272029B2Interferon lambada-antibody complexesIBC PHARMACEUTICALS INC·Filed 2013·Granted Mar 1, 2016·7 cites·6 claims
- 2789US8883162B2Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumorsIBC PHARMACEUTICALS INC·Filed 2012·Granted Nov 11, 2014·7 cites·20 claims
- 2886US10022427B2Interferon lambda-antibody complexesIBC PHARMACEUTICALS INC·Filed 2016·Granted Jul 17, 2018·4 cites·17 claims
- 2985US9550838B2Dock-and-lock (DNL) complexes for therapeutic and diagnostic useIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 24, 2017·3 cites·1 claims
- 3081US9416197B2Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune diseaseIBC PHARMACEUTICALS INC·Filed 2014·Granted Aug 16, 2016·1 cites·12 claims
- 3179US9359443B2Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseasesIBC PHARMACEUTICALS INC·Filed 2014·Granted Jun 7, 2016·1 cites·4 claims
- 3278US8906378B2Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseasesIBC PHARMACEUTICALS INC·Filed 2013·Granted Dec 9, 2014·2 cites·7 claims
- 3374US9540435B2Stably tethered structures of defined compositions with multiple functions or binding specificitiesIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·1 cites·8 claims
- 3473US9737617B2Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseasesIBC PHARMACEUTICALS INC·Filed 2014·Granted Aug 22, 2017·0 cites·17 claims
- 3572US9446123B2Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacyIBC PHARMACEUTICALS INC·Filed 2013·Granted Sep 20, 2016·1 cites·2 claims
- 3671US9169470B2Methods and compositions for generating bioactive assemblies of increased complexity and usesIBC PHARMACEUTICALS INC·Filed 2014·Granted Oct 27, 2015·0 cites·5 claims
- 3770US10385139B2Murine, chimeric, humanized or human anti-TNF-alpha antibodiesIBC PHARMACEUTICALS INC·Filed 2018·Granted Aug 20, 2019·0 cites·10 claims
- 3869US9932413B2Murine, chimeric, humanized or human anti-IL-6 antibodiesIBC PHARMACEUTICALS INC·Filed 2017·Granted Apr 3, 2018·0 cites·3 claims
- 3968US2019142939A1Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4066US9540618B2Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and usesIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·0 cites·4 claims
- 4165US9498542B2Tetrameric cytokines with improved biological activityIBC PHARMACEUTICALS INC·Filed 2013·Granted Nov 22, 2016·0 cites·6 claims
- 4264US10183992B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2017·Granted Jan 22, 2019·0 cites·6 claims
- 4364US9862770B2Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumorsIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 9, 2018·0 cites·27 claims
- 4463US10239938B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2016·Granted Mar 26, 2019·0 cites·5 claims
- 4563US2016311931A1Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune diseaseIBC PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4662US9872920B2PEGylation by the dock and lock (DNL) techniqueIBC PHARMACEUTICALS INC·Filed 2016·Granted Jan 23, 2018·0 cites·13 claims
- 4762US2015374846A1Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and UsesIBC PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4861US9248184B2Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapyIBC PHARMACEUTICALS INC·Filed 2013·Granted Feb 2, 2016·0 cites·9 claims
- 4961US2016361405A1Dock-and-Lock (DNL) Vaccines for Cancer TherapyIBC PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 5060US10308688B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2016·Granted Jun 4, 2019·0 cites·11 claims
Showing the top 50 of 64 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →